Bosutinib differs from other tyrosine kinase inhibitors (TKIs) due to its dual inhibition of BCR-ABL1 and SRC family kinases, providing efficacy against certain BCR-ABL1 mutations resistant to first-generation TKIs like imatinib. It lacks significant activity against KIT or PDGFR, minimizing off-target effects.